Literature DB >> 1316826

Overrunning and underrunning in sequential clinical trials.

J Whitehead1.   

Abstract

In a sequential (or group sequential) clinical trial the fulfillment of some pre-specified stopping rule will cause recruitment to be terminated. However, for various reasons, data on patients treated according to protocol may continue to accumulate for some time afterward. This phenomenon is called overrunning. On the other hand, a sequential clinical trial might be abandoned before the stopping rule has been fulfilled. This is called underrunning. In both of these situations the procedure for validly analyzing the study is unclear. In this paper we first review the arguments for sequential methodology and the practical way in which it can be integrated with normal clinical trial conduct. Turning next to the special situations of overrunning and underrunning, the conditions under which a valid analysis is possible are identified, and a method of analysis based on the frequentist philosophy is presented. The likelihood of first gaining and then losing significance due to overrunning and its consequences are examined. Examples based on experience with real studies are presented.

Entities:  

Mesh:

Year:  1992        PMID: 1316826     DOI: 10.1016/0197-2456(92)90017-t

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  15 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.

Authors:  Achilles A Demetriou; Robert S Brown; Ronald W Busuttil; Jeffrey Fair; Brendan M McGuire; Philip Rosenthal; Jan Schulte Am Esch; Jan Lerut; Scott L Nyberg; Mauro Salizzoni; Elizabeth A Fagan; Bernard de Hemptinne; Christoph E Broelsch; Maurizio Muraca; Joan Manuel Salmeron; John M Rabkin; Herold J Metselaar; Daniel Pratt; Manuel De La Mata; Lawrence P McChesney; Gregory T Everson; Philip T Lavin; Anthony C Stevens; Zorina Pitkin; Barry A Solomon
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

3.  Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial.

Authors:  Julia C Dombrowski; Michael R Wierzbicki; Lori M Newman; Jonathan A Powell; Ashley Miller; Dwyn Dithmer; Olusegun O Soge; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2021-09-07       Impact factor: 9.079

4.  Interim analyses and stopping rules in cancer clinical trials.

Authors:  J Whitehead
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

5.  A simulated sequential analysis based on data from two MRC trials.

Authors:  A N Donaldson; J Whitehead; R Stephens; D Machin
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

6.  GOST: A generic ordinal sequential trial design for a treatment trial in an emerging pandemic.

Authors:  John Whitehead; Peter Horby
Journal:  PLoS Negl Trop Dis       Date:  2017-03-09

7.  Trial design for evaluating novel treatments during an outbreak of an infectious disease.

Authors:  John Whitehead; Piero Olliaro; Trudie Lang; Peter Horby
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

8.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

9.  Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.

Authors:  Carsten Hirt; Eva Hoster; Michael Unterhalt; Mathias Hänel; Gabriele Prange-Krex; Roswitha Forstpointner; Axel Florschütz; Ullrich Graeven; Norbert Frickhofen; Gerald Wulf; Eva Lengfelder; Christian Lerchenmüller; Rudolf Schlag; Judith Dierlamm; Ludwig Fischer von Weikersthal; Asima Ahmed; Hanns-Detlev Harich; Andreas Rosenwald; Wolfram Klapper; Martin Dreyling; Wolfgang Hiddemann; Michael Herold
Journal:  Hemasphere       Date:  2021-06-23

10.  An Application of Sequential Meta-Analysis to Gene Expression Studies.

Authors:  Putri W Novianti; Ingeborg van der Tweel; Victor L Jong; Kit Cb Roes; Marinus Jc Eijkemans
Journal:  Cancer Inform       Date:  2015-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.